Business Context and Reporting Period
This Form 6-K filing is submitted by Novartis AG, a Swiss-based foreign private issuer, on March 9, 2010. The report serves to incorporate specific financial exhibits by reference into the company's Registration Statement on Form F-3 (File No. 333-153696) for Novartis AG and its subsidiaries (Novartis Capital Corporation, Novartis Securities Investment Ltd., and Novartis Finance S.A.).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document references the inclusion of an exhibit titled "Statement of Computation of Ratio of Earnings to Fixed Charges" (Exhibit 12.1) but does not display the numerical data within the body of this report.
Material Changes
No material changes regarding financial performance or operations are described in the text of this filing. The document is procedural in nature, focusing on the incorporation of exhibits into a registration statement.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is limited to the administrative act of incorporating Exhibit 12.1 into the Form F-3 registration statement.
Investor Verification Checklist
- Verify the specific numerical data in Exhibit 12.1 (Statement of Computation of Ratio of Earnings to Fixed Charges) which is incorporated by reference but not detailed in this text.
- Review the full Form F-3 Registration Statement (File No. 333-153696) to understand the context of the securities offering.
- Confirm the identity of the authorized signatory, Malcolm B. Cheetham, Head Group Financial Reporting and Accounting.